Human lifelong immunity depends on APRIL

Islamabad: Researchers from Tokyo Medical and Dental University (TMDU) identify the protein APRIL as a cause for antibody deficiency in humans, and as a key regulator of plasmacyte maintenance and immunoglobulin production.

The immune system depends on a complex interaction between various cells for proper functioning. In a new study, researchers from Tokyo Medical and Dental University (TMDU) discovered that an absence of the protein APRIL in humans results in the underdevelopment of antibody-producing plasmacytes causing common variable immunodeficiency (CVID), a condition which is characterized by increased susceptibility to infections of affected patients.

Plasmacytes, whose lifelong task is to keep producing immunoglobulins, are a key component of the immune system. They develop when B cells, a type of immune cell, are activated by T cells and other blood cells, called myeloid cells, and switch from producing low-quality to high-quality antibodies. Because each plasmacyte produces one specific antibody, their development is closely regulated and thus depends on a complex interaction between B cells and myeloid cells. A protein that is part of this process is APRIL (A PRoliferation-Inducing Ligand), which is produced by myeloid cells to induce the development of plasmacytes from B cells. Could defects in APRIL result in immunodeficiency in humans? Until now this was unknown.

“There are countless components within the complex immune system machinery,” says corresponding author Kohsuke Imai. “Disrupting one of them can severely decrease the immune system’s ability to fight infections. The goal of our study was to understand how a deficiency of APRIL affects the human immune system.”

To achieve their goal, the researchers sequenced all protein-coding part of DNA of a patient with CVID and found a mutation in the gene encoding APRIL, resulting in an absence of APRIL in the patient’s blood. Upon closer investigation of the makeup of the patient’s blood cells, the researchers found that the patient had increased levels of marzinal zone B cells and reduced levels of plasmacytes and immunoglobulins.

“These findings suggest that a deficiency of APRIL disrupts the development of immunoglobulin-producing plasmacytes,” says lead author Tzu-Wen Yeh. “Our next goal was to determine if APRIL not only correlates with, but also causes immunodeficiency.”

The researchers isolated blood cells from the patient and reprogrammed them to become induced pluripotent stem cells (iPSCs), which have the capability of producing any cell of the body. Because the patient had a genetic mutation in the gene encoding APRIL, the iPSCs did so too.

The researchers then differentiated the iPSCs to monocyte-derived dendritic cells(iPSC-moDCs), which induce plasmacyte differentiation from B cells. When the patient derived iPSC-moDCs were cocultured with B cells from healthy controls the researchers found that plasmacyte differentiation was impaired, again showing that APRIL plays an important role in plasmacyte development. However, when the researchers added recombinant APRIL to the coculture, plasmacyte development was rescued, demonstrating that the absence of APRIL was the cause in the patient’s CVID.

“These are striking results that show how APRIL has an essential function in the proper functioning of the immune system,” says Kohsuke Imai. “Our findings provide new insights into plasmacyte maintenance and immunoglobulin production. To our knowledge, our study provides the first report to show that deficiency in APRIL is linked to common variable immunodeficiency in humans. Substitution of recombinant APRIL in congenital or acquired APRIL deficiency might even be a potential novel treatment for the immunodeficiency due to hypogammaglobulinemia.”